{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:54:40Z","timestamp":1792806880384,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005061.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T00:00:00Z","timestamp":1545955200000}}],"reference-count":140,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005061.pub3","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T20:11:56Z","timestamp":1546027916000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus"],"prefix":"10.1002","volume":"2018","author":[{"given":"Suzanne VL","family":"Moelands","sequence":"first","affiliation":[{"name":"Radboud University Nijmegen Medical Center; Department of Primary and Community Care; PO Box 9101 Nijmegen Netherlands 6500 HB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter LBJ","family":"Lucassen","sequence":"additional","affiliation":[{"name":"Radboud University Nijmegen Medical Center; Department of Primary and Community Care; PO Box 9101 Nijmegen Netherlands 6500 HB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier P","family":"Akkermans","sequence":"additional","affiliation":[{"name":"Radboud University Nijmegen Medical Center; Department of Primary and Community Care; PO Box 9101 Nijmegen Netherlands 6500 HB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim JC","family":"De Grauw","sequence":"additional","affiliation":[{"name":"Radboud University Nijmegen Medical Center; Department of Primary and Community Care; PO Box 9101 Nijmegen Netherlands 6500 HB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris A","family":"Van de Laar","sequence":"additional","affiliation":[{"name":"Radboud University Nijmegen Medical Center; Department of Primary and Community Care; PO Box 9101 Nijmegen Netherlands 6500 HB"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,28]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10557-017-6740-3","article-title":"Does treatment of impaired glucose tolerance improve cardiovascular outcomes in patients with previous myocardial infarction?","volume":"31","author":"Asakura","year":"2017","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0002|cit2","unstructured":"NCT00212017 Assessment of an alpha-glucosidase inhibitor to block cardiac events in patients with myocardial infarction and IGT (ABC Study) www.clinicaltrials.gov\/ct2\/show\/NCT00212017"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0003|cit3","unstructured":"Diabetes Trials Unit University of Oxford Acarbose cardiovascular evaluation www.dtu.ox.ac.uk\/ACE"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2014.03.021","article-title":"Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial","volume":"168","author":"Holman","year":"2014","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes & Endocrinology"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0006|cit6","unstructured":"ISRCTN91899513 Acarbose Cardiovascular Evaluation trial (ACE) www.isrctn.com\/ISRCTN91899513"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0007|cit7","unstructured":"NCT00829660 Acarbose Cardiovascular Evaluation Trial (ACE) www.clinicaltrials.gov\/ct2\/show\/NCT00829660"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0008|cit8","unstructured":"ISRCTN33274262 Dutch acarbose intervention trial (DAISI) www.isrctn.com\/ISRCTN33274262"},{"issue":"8","key":"10.1002\/14651858.CD005061.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/dmrr.839","article-title":"A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch Acarbose Intervention Study in persons with impaired glucose tolerance (DAISI)","volume":"24","author":"Nijpels","year":"2008","journal-title":"Diabetes\/metabolism Research and Reviews"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0010|cit10","first-page":"A73","article-title":"Possible prevention of type 2 diabetes with acarbose or metformin over three years","volume":"43","author":"Citro\u00ebn","year":"2000","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0011|cit11","unstructured":"Diabetes Trials Unit University of Oxford Early diabetes intervention trial (protocol) www.dtu.ox.ac.uk\/EDIT\/protocol"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0012|cit12","first-page":"A16","article-title":"Results from the Early Diabetes Intervention Trial","volume":"52","author":"Holman","year":"2003","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005061.pub3-BIB0013|cit13","first-page":"15","article-title":"Six-years results from the Early Diabetes Intervention Trial","volume":"20","author":"Holman","year":"2003","journal-title":"Diabetic Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0014|cit14","first-page":"157A","article-title":"Early Diabetes Intervention Trial","volume":"46","author":"Holman","year":"1997","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0015|cit15","first-page":"A17","article-title":"Early Diabetes Intervention Trial","volume":"40","author":"Holman","year":"1997","journal-title":"Diabetologia"},{"issue":"Suppl 1: A111","key":"10.1002\/14651858.CD005061.pub3-BIB0016|cit16","first-page":"450","article-title":"Possible prevention of type 2 diabetes with acarbose or metformin","volume":"49","author":"Holman","year":"2000","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0017|cit17","unstructured":"ISRCTN96631607 Early diabetes intervention trial (EDIT study) www.isrctn.com\/ISRCTN96631607"},{"issue":"suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0018|cit18","first-page":"A122","article-title":"The haemoglobin glycation index is reproducible in dysglycaemic individual but is not explained by post-challenge plasma glucose levels [Abstract]","volume":"47","author":"Kim","year":"2004","journal-title":"Diabetologia"},{"issue":"30","key":"10.1002\/14651858.CD005061.pub3-BIB0019|cit19","first-page":"6562","article-title":"Effect of medicine and non-medicine intervention on the outcomes of patients with impaired glucose tolerance: 5-year follow-up","volume":"8","author":"Fang","year":"2004","journal-title":"Zhongguo Linchuang Kangfu [Chinese Journal for Clinical Rehabilitation]"},{"issue":"9675","key":"10.1002\/14651858.CD005061.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(09)60222-1","article-title":"Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance","volume":"373","author":"Kawamori","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0021|cit21","unstructured":"UMIN000001109 A study in subjects with impaired glucose tolerance (IGT) to evaluate effects of AO-128 on prevention of type 2 diabetes mellitus upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000001296"},{"issue":"9","key":"10.1002\/14651858.CD005061.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.clinthera.2010.07.015","article-title":"Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease","volume":"32","author":"Koyasu","year":"2010","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0023|cit23","unstructured":"UMIN000000544 Impact of acarbose therapy in abnormal glucose tolerance patients with coronary artery disease upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000000658"},{"issue":"38 Suppl","key":"10.1002\/14651858.CD005061.pub3-BIB0024|cit24","first-page":"1","article-title":"The \"STOP NIDDM\" program - can diabetes in the aged be prevented? An international long-term study revisited; does acarbose delay or prevent the manifestations of type II diabetes","volume":"122","author":"Anonymous","year":"1997","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0025|cit25","unstructured":"Anonymous The STOP-NIDDM trial study to prevent non insulin dependent diabetes mellitus [PowerPoint presentation] www.stop-niddm.com\/study\/slides\/htm (accessed 1 August 2006; no longer available) 2003"},{"issue":"23","key":"10.1002\/14651858.CD005061.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1001\/jama.290.23.3066-c","article-title":"Acarbose for patients with hypertension and impaired glucose tolerance","volume":"290","author":"Bridges","year":"2003","journal-title":"JAMA"},{"issue":"Supplement D","key":"10.1002\/14651858.CD005061.pub3-BIB0032|cit27","first-page":"D35","article-title":"The potential use of acarbose in the prevention of type 2 diabetes and cardiovascular disease","volume":"2","author":"Chiasson","year":"2000","journal-title":"European Heart Journal Supplements"},{"issue":"10","key":"10.1002\/14651858.CD005061.pub3-BIB0027|cit28","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/diacare.21.10.1720","article-title":"The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus","volume":"21","author":"Chiasson","year":"1998","journal-title":"Diabetes Care"},{"issue":"9323","key":"10.1002\/14651858.CD005061.pub3-BIB0028|cit29","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD005061.pub3-BIB0029|cit30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00125-004-1409-4","article-title":"Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data","volume":"47","author":"Chiasson","year":"2004","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0030|cit31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005061.pub3-BIB0031|cit32","first-page":"A104","article-title":"Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: the STOP-NIDDM Trial","volume":"45","author":"Chiasson","year":"2002","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD005061.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.coph.2004.11.005","article-title":"Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus","volume":"5","author":"Delorme","year":"2005","journal-title":"Current Opinion in Pharmacology"},{"issue":"23","key":"10.1002\/14651858.CD005061.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1001\/jama.290.23.3067-a","article-title":"Acarbose for patients with hypertension and impaired glucose tolerance","volume":"290","author":"Gonzalez-Clemente","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD005061.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/01.STR.0000125864.01546.f2","article-title":"Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance","volume":"35","author":"Hanefeld","year":"2004","journal-title":"Stroke"},{"issue":"23","key":"10.1002\/14651858.CD005061.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1001\/jama.290.23.3066-b","article-title":"Acarbose for patients with hypertension and impaired glucose tolerance","volume":"290","author":"Kaiser","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00125-003-1318-y","article-title":"Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data","volume":"47","author":"Kaiser","year":"2004","journal-title":"Diabetologia"},{"issue":"9344","key":"10.1002\/14651858.CD005061.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(02)11458-9","article-title":"Acarbose for type 2 diabetes prevention","volume":"360","author":"Muhlhauser","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD005061.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1368-5031.2005.00629.x","article-title":"Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden","volume":"59","author":"Quilici","year":"2005","journal-title":"International Journal of Clinical Practice"},{"issue":"23","key":"10.1002\/14651858.CD005061.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1001\/jama.290.23.3066-a","article-title":"Acarbose for patients with hypertension and impaired glucose tolerance","volume":"290","author":"Rosenthal","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD005061.pub3-BIB0041|cit41","first-page":"431","article-title":"Cost-effectiveness analysis of acarbose in the treatment of patients with impaired glucose tolerance","volume":"18","author":"Sabes","year":"2004","journal-title":"Gaceta Sanitaria \/ S.E.S.P.A.S"},{"issue":"6","key":"10.1002\/14651858.CD005061.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00125-004-1410-y","article-title":"Response to Chiasson et al.: Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data","volume":"47","author":"Sawicki","year":"2004","journal-title":"Diabetologia"},{"issue":"9344","key":"10.1002\/14651858.CD005061.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/S0140-6736(02)11457-7","article-title":"Acarbose for type 2 diabetes prevention","volume":"360","author":"Scheen","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005061.pub3-BIB0044|cit44","first-page":"A122","article-title":"Lower progression of carotid intima media thickness under acarbose: the STOP-NIDDM study","volume":"46","author":"Temelkova-Kurktschiev","year":"2003","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00108-003-0871-2","article-title":"Acarbose for prevention of diabetes mellitus. STOP-NIDDM","volume":"44","author":"Windler","year":"2003","journal-title":"Der Internist"},{"issue":"1","key":"10.1002\/14651858.CD005061.pub3-BIB0047|cit46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2005.02.033","article-title":"Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes","volume":"107","author":"Zeymer","year":"2006","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD005061.pub3-BIB0048|cit47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2005.02.033","article-title":"Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy","volume":"107","author":"Zeymer","year":"2006","journal-title":"International Journal of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0046|cit48","first-page":"A47","article-title":"Acarbose reduces silent myocardial infarctions in patients with impaired glucose tolerance. Results of the randomized STOP-NIDDM ECG substudy","volume":"47","author":"Zeymer","year":"2004","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD005061.pub3-BIB0049|cit49","first-page":"116","article-title":"An evalualion on efficacy of acarbose interfering trentment on IGT","volume":"9","author":"Wang","year":"2000","journal-title":"Shanxi Clinical Medicine Journal"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1602083","DOI":"10.1155\/2016\/1602083","article-title":"Effect of acarbose on long-term prognosis in acute coronary syndromes patients with newly diagnosed impaired glucose tolerance","volume":"2016","author":"Yun","year":"2016","journal-title":"Journal of Diabetes Research"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0051|cit51","unstructured":"NCT01167231 Prevention of postprandial hyperglycemia by acarbose may be a promising therapeutic strategy for reducing the increased risk for cardiovascular disease (ABDOMEN) www.clinicaltrials.gov\/ct2\/show\/NCT01167231"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0052|cit52","unstructured":"UMIN000003170 Effect of miglitol and sitagliptin on incretin levels upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000003662"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2337\/diacare.24.3.465","article-title":"HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP)","volume":"24","author":"Perry","year":"2001","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0054|cit54","first-page":"A132","article-title":"Acarbose in 'early' diabetes - data from the Early Diabetes Intervention Program (EDIP)","volume":"54","author":"Shankar","year":"2005","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0055|cit55","unstructured":"UMIN000000681 A randomized comparative clinical study on suppression of progression from early diabetes, diet\/exercise standard intervention vs. concurrent pharmacological standard intervention upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000000817"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1253\/circj.CJ-11-1011","article-title":"Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients","volume":"76","author":"Kataoka","year":"2012","journal-title":"Circulation Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005061.pub3-BIB0057|cit57","first-page":"276","article-title":"Effects of acarbose in patients with beta-thalassaemia major and abnormal glucose homeostasis","volume":"2","author":"Mangiagli","year":"2004","journal-title":"Pediatric Endocrinology Reviews"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0058|cit58","unstructured":"2004-002579-17 A double-blind, randomised placebo controlled study of the effects of acarbose on endothelial function, hemostatic and fibrinolytic plasmatic factors in patients with stable coronary artery disease and either impaired glucose intolerance or newly diagnosed diabetes mellitus www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002579-17\/DE"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0059|cit59","unstructured":"UMIN000010282 Three-arm comparative study of miglitol and mitiglinide alone and in combination -efficacy and safety studies upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000012031"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0060|cit60","unstructured":"UMIN000001671 The comparative study of the effects of miglitol and voglibose (alpha-glucosidase inhibitors) on incretins secretion upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000002020"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0061|cit61","unstructured":"NCT00417950 Additional glucose lowering and anti-inflammatory effects by acarbose and alcohol in subjects with impaired glucose tolerance or mild type 2 diabetes www.clinicaltrials.gov\/ct2\/show\/NCT00417950"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0062|cit62","unstructured":"UMIN000008692 Study of the combination use effect of DPP-4 inhibitor and alpha-glucosidase inhibitor upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000010217"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0063|cit63","unstructured":"UMIN000008591 Linagliptin study of effects on PPG, postprandial blood glucose control upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000010093"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0064|cit64","first-page":"131","article-title":"The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study [Chinese translation from Bayer website www.stop-niddm.com, accessed 13 September 2004, no longer available]","volume":"17","author":"Yang","year":"2001","journal-title":"Chinese Journal of Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0065|cit65","unstructured":"NCT00221156 Acarbose and secondary prevention after coronary stenting www.clinicaltrials.gov\/ct2\/show\/NCT00221156"},{"issue":"5","key":"10.1002\/14651858.CD005061.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"s33","DOI":"10.2337\/diacare.26.2007.S33","article-title":"Standards of medical care for patients with diabetes mellitus","volume":"26","author":"American Diabetes Association","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0069|cit69","unstructured":"American Diabetes Association Strategies for effective screening, intervention and follow-up professional.diabetes.org\/slidelibrary\/prediabetes-strategies-effective-screening-intervention-and-follow"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005061.pub3-BIB0070|cit70","first-page":"S1","article-title":"Standards of medical care in diabetes-2015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD005061.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","article-title":"Cardiovascular disease risk profiles","volume":"121","author":"Anderson","year":"1991","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/pon.3205","article-title":"Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures","volume":"22","author":"Bell","year":"2013","journal-title":"Psycho-oncology"},{"issue":"1","key":"10.1002\/14651858.CD005061.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I\u00b2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0074|cit74","unstructured":"Borenstein M Prediction intervals www.meta-analysis.com\/prediction"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2014.56.7503","article-title":"Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial","volume":"32","author":"Boutron","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/00325481.2017.1265417","article-title":"Long-term studies of treatments for type 2 diabetes","volume":"129","author":"Caballero","year":"2016","journal-title":"Postgraduate Medicine"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0077|cit77","unstructured":"Centers for Disease Control and Prevention 2014 National Diabetes Statistics Report www.cdc.gov\/diabetes\/pdfs\/data\/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf"},{"issue":"11","key":"10.1002\/14651858.CD005061.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/diacare.19.11.1190","article-title":"The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance","volume":"19","author":"Chiasson","year":"1996","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD005061.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-122-7-199504010-00001","article-title":"Weight gain as a risk factor for clinical diabetes mellitus in women","volume":"122","author":"Colditz","year":"1995","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2014","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0081|cit81","unstructured":"Deeks JJ Higgins JP Altman DG (editors) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","article-title":"Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake","volume":"38","author":"DeFronzo","year":"1989","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"6","key":"10.1002\/14651858.CD005061.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"9702","key":"10.1002\/14651858.CD005061.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2337\/dc13-2195","article-title":"Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis","volume":"37","author":"Dunkley","year":"2014","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1002\/14651858.CD005061.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MAJ.0000000000000223","article-title":"Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice","volume":"348","author":"Gosmanov","year":"2014","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0088|cit88","unstructured":"McMaster University, 2015 (developed by Evidence Prime, Inc.) GRADEpro GDT 2015"},{"issue":"10","key":"10.1002\/14651858.CD005061.pub3-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012151","article-title":"Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012106.pub2","article-title":"Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD005061.pub3-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003054.pub4","article-title":"Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus","author":"Hemmingsen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD005061.pub3-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012204.pub2","article-title":"Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD005061.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD005061.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD005061.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"Journal of the Royal Statistical Society: Series A (Statistics in Society)"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0096|cit96","unstructured":"Higgins JP Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD005061.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1741826711421687","article-title":"Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials","volume":"18","author":"Hopper","year":"2011","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1503\/cmaj.120744","article-title":"Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors","volume":"185","author":"Hr\u00f3bjartsson","year":"2013","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0099|cit99","unstructured":"International Conference on Harmonisation Expert Working Group International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice \/\/1997 CFR & ICH Guidelines PA 19063-2043 USA Barnett International\/PAREXEL 1997"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0100|cit100","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2017"},{"issue":"7","key":"10.1002\/14651858.CD005061.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","author":"International Expert Committee","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD005061.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00125-012-2715-x","article-title":"The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study","volume":"56","author":"Scott","year":"2013","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD005061.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2337\/diacare.16.2.499","article-title":"Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity","volume":"16","author":"Jenney","year":"1993","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD005061.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.2337\/diabetes.51.7.2170","article-title":"Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S","volume":"51","author":"Jensen","year":"2002","journal-title":"Diabetes"},{"issue":"6","key":"10.1002\/14651858.CD005061.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2337\/diacare.19.6.559","article-title":"Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?","volume":"19","author":"Johnson","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00125-003-1318-y","article-title":"Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data","volume":"47","author":"Kaiser","year":"2004","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD005061.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2337\/dc06-0061","article-title":"Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program","volume":"29","author":"Kirkman","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD005061.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2337\/diabetes.48.5.937","article-title":"Hyperglycemia and cardiovascular disease in type 2 diabetes","volume":"48","author":"Laakso","year":"1999","journal-title":"Diabetes"},{"issue":"7","key":"10.1002\/14651858.CD005061.pub3-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jama.2009.1242","article-title":"Comparison of registered and published primary outcomes in randomized controlled trials","volume":"302","author":"Mathieu","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD005061.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.21.2.256","article-title":"Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients","volume":"21","author":"Matsumoto","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD005061.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2337\/diabetes.49.12.2201","article-title":"Parental transmission of type 2 diabetes: the Framingham Offspring Study","volume":"49","author":"Meigs","year":"2000","journal-title":"Diabetes"},{"issue":"8","key":"10.1002\/14651858.CD005061.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2337\/diacare.23.8.1162","article-title":"Effect of acarbose on insulin sensitivity in elderly patients with diabetes","volume":"23","author":"Meneilly","year":"2000","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD005061.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00125-013-2902-4","article-title":"Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis","volume":"56","author":"Morris","year":"2013","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11695-010-0335-4","article-title":"Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006","volume":"21","author":"Nguyen","year":"2011","journal-title":"Obesity Surgery"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"183-90","DOI":"10.1016\/S0168-8227(03)00117-7","article-title":"Efficacy of acarbose in Chinese subjects with impaired glucose tolerance","volume":"61","author":"Pan","year":"2003","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD005061.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1368-5031.2005.00629.x","article-title":"Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden","volume":"59","author":"Quilici","year":"2005","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0120|cit120","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD005061.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00125-004-1410-y","article-title":"Response to Chiasson et al.: acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data","volume":"47","author":"Sawicki","year":"2004","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0123|cit123","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD005061.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-154-5-201103010-00004","article-title":"Racial differences in glycemic markers: a cross-sectional analysis of community-based data","volume":"154","author":"Selvin","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005061.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0026-0495(96)90139-0","article-title":"Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects","volume":"45","author":"Shinozaki","year":"1996","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"8","key":"10.1002\/14651858.CD005061.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"575","DOI":"10.7326\/0003-4819-136-8-200204160-00006","article-title":"Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?","volume":"136","author":"Stern","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD005061.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.diabres.2015.01.027","article-title":"Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions","volume":"107","author":"Stevens","year":"2015","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"9467","key":"10.1002\/14651858.CD005061.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 diabetes: principles of pathogenesis and therapy","volume":"365","author":"Stumvoll","year":"2005","journal-title":"Lancet"},{"issue":"9833","key":"10.1002\/14651858.CD005061.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","article-title":"Prediabetes: a high-risk state for diabetes development","volume":"379","author":"Tabak","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD005061.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD005061.pub3-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003639.pub2","article-title":"Alpha-glucosidase inhibitors for type 2 diabetes mellitus","author":"Laar","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0133|cit133","unstructured":"World Health Organisation Technical Report Series No. 727. Report of a WHO Study Group WHO Expert Committee on Diabetes Mellitus 1985"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0135|cit135","unstructured":"World Health Organization\/International Diabetes Federation Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation www.who.int\/diabetes\/publications\/Definition%20and%20diagnosis%20of%20diabetes_new.pdf"},{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0136|cit136","first-page":"451","article-title":"Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and Embase","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"1","key":"10.1002\/14651858.CD005061.pub3-BIB0137|cit137","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in Embase","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"7644","key":"10.1002\/14651858.CD005061.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005061.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"g4485","DOI":"10.1136\/bmj.g4485","article-title":"The epidemic of pre-diabetes: the medicine and the politics","volume":"349","author":"Yudkin","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD005061.pub3-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005061.pub2","article-title":"Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose","author":"Laar","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005061.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:49:34Z","timestamp":1662706174000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005061.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,28]]},"references-count":140,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005061.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,28]]}}}